As of 2026-03-14, the Intrinsic Value of TME Pharma NV (ALTME.PA) is -0.24 EUR. This ALTME.PA valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 EUR, the upside of TME Pharma NV is -405.94%.
Based on its market price of 0.08 EUR and our intrinsic valuation, TME Pharma NV (ALTME.PA) is overvalued by 405.94%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.24 - -0.24 | -0.24 | -405.94% |
| DDM - Stable | (0.85) - (10.35) | (5.60) | -7157.8% |
| DDM - Multi | (1.06) - (9.90) | (1.91) | -2500.9% |
| Market Cap (mil) | 7.48 |
| Beta | -0.09 |
| Outstanding shares (mil) | 94.19 |
| Enterprise Value (mil) | 7.48 |
| Market risk premium | 5.82% |
| Cost of Equity | 6.20% |
| Cost of Debt | 5.00% |
| WACC | 4.94% |